Heartseed and ITOCHU CHEMICAL FRONTIER Sign Capital Alliance Agreement to Explore iPSC and Cardiomyocyte Business Opportunities

TOKYO–(BUSINESS WIRE)–#biotech–Heartseed Inc. (hereinafter Heartseed), a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for the treatment of heart failure (HF), today announced it has entered into agreement with ITOCHU CHEMICAL FRONTIER Corporation (headquartered in Minato-ku, Tokyo; President & CEO Tsutomu Miyazaki, hereinafter ICF) to form a financial business partnership. In accordance with the partnership, ICF will invest in Heartseed in an extension round of its Series B financing.

ICF is a fully owned subsidiary of ITOCHU Corporation, one of the largest general trading companies, and plays a key role in fine and specialty organic chemicals in the group.

Through this partnership, Heartseed will leverage ICF’s global network of academia and research institutions to explore iPS-Cell and Cardiomyocyte-related business opportunities.

Heartseed previously announced it raised 2.8 billion yen (approx. US$26 million) in the Series B in November 2019 from SBI Investment, JMDC, Gene Techno Science, Nissay Capital, SMBC Venture Capital, and Astellas Venture Management LLC.

Heartseed expects to initiate Phase 1/2 clinical trial for its lead pipeline HS-001 for HF with reduced Ejection Fraction (HFrEF) in late 2020. Heartseed is also supporting an investigator-initiated clinical trial for Dilated Cardiomyopathy led by Keio University. Keio University expert panel approved its clinical trial plan in February 2020.

About Heartseed

Heartseed Inc. was founded in 2015 to develop and commercialize cardiac regenerative medicine developed by Prof. Keiichi Fukuda and his group at the Department of Cardiology, Keio University, Tokyo. Heartseed has original technologies throughout the process of manufacturing and delivering iPSC-derived cardiac regenerative medicine, including purification, cell delivery and iPSC production.

Company Name:	Heartseed Inc.
Established:	November 30, 2015
President :	Keiichi Fukuda
Headquarter:	Art Complex Center 302, Daikyocho 12-9, Shinjuku-ku, Tokyo, Japan
Shareholders:	Founders/Employees/Angel Bridge/Astellas Venture Management/Shibuya Corporation/ SBI Investment, JMDC, Gene Techno Science, Nissay Capital, SMBC Venture Capital
Website:	http://www.heartseed.jp/en/index.html

For more information on Heartseed, please visit http://www.heartseed.jp/en/index.html

Contacts

Kikuo Yasui,

COO, Heartseed Inc.

Tel: +81-3-6380-1068

Email: kikuo.yasui@heartseed.jp